Rhythm Pharmaceuticals
RYTM
105 hedge funds and large institutions have $905M invested in Rhythm Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 42 increasing their positions, 33 reducing their positions, and 26 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 33
0.24% less ownership
Funds ownership: 94.81% → 94.57% (-0.24%)
11% less capital invested
Capital invested by funds: $1.01B → $905M (-$106M)
15% less funds holding
Funds holding: 124 → 105 (-19)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
73% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 26
92% less call options, than puts
Call options by funds: $68K | Put options by funds: $800K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$8.49M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$7.96M |
| 3 |
Morgan Stanley
New York
|
+$7.18M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.83M |
| 5 |
BlackRock
New York
|
+$3.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
-$11.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.45M |
| 3 |
Two Sigma Investments
New York
|
-$4.93M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$3.8M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$3.6M |
RYTM Hedge Fund Activity: Q2 2021 in Review
105 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q2 2021, worth a combined $905M — down 11% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of RYTM and 7 opened new positions — a net loss of 19 holders — while 33 trimmed existing stakes and 42 added.
The largest buyer was Goldman Sachs, adding an estimated $8.49M. The largest seller was CAAS Capital Management, cutting an estimated $11.1M.
- 105 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q2 2021, down from 124 in Q1 2021.
- Funds reported $905M of Rhythm Pharmaceuticals stock for Q2 2021, down 11% quarter-over-quarter.
- 7 funds opened new Rhythm Pharmaceuticals positions in Q2 2021 and 26 closed out, a net change of -19 holders.
- The largest Rhythm Pharmaceuticals buyer in Q2 2021 was Goldman Sachs, an estimated $8.49M added.
- The largest Rhythm Pharmaceuticals seller in Q2 2021 was CAAS Capital Management, an estimated $11.1M sold.
Based on aggregated 13F filings for Q2 2021.